Product Details
Brigatinib for Tablets BP
Product Name
:
Brigatinib for Tablets BP
Brand Name
:
VERBRIGA
Available Strength
:
180 mg
Packing
:
30 Tablets
Pack Insert/Leaflet
:
According To Your Needs
These film-coated tablets meet British Pharmacopoeia standards, supporting targeted treatment for ALK-positive non-small cell lung cancer. Oncologists prescribe Brigatinib for patients whose tumors test positive for ALK gene rearrangements, including those who have progressed on prior ALK-targeted therapy.
Brigatinib BP (180 mg) is a tyrosine kinase inhibitor that blocks ALK signaling, interrupting the growth pathway driving ALK-positive tumors. As a result, it helps control tumor progression in eligible patients. Because of this targeted mechanism, oncology specialists prescribe it under close supervision as part of an individualized treatment plan. Therefore, hospitals and oncology clinics restrict its use to patients under specialist care.
Key Features
- Meets BP (British Pharmacopoeia) standards for consistent quality
- Delivers targeted ALK inhibition for lung cancer therapy
- Ensures accurate, validated dosing in every batch
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncologist supervision
- Restricted to hospital, oncology clinic, and specialist institutional supply